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SUMMARY 
Hypercortisolaemia is a feature of many severe psychiatric illnesses and has been 
suggested to be both a causal and exacerbating factor of clinical symptoms and 
neurocognitive impairment. The adrenal steroid dehydroepiandrosterone (DHEA) 
has antiglucocorticoid properties that may have regulatory effects on 
glucocorticoid action in the brain. However, there is a paucity of data on these 
steroids and their ratio in schizophrenia and bipolar disorder. We therefore sought 
to assess cortisol and DHEA levels and the cortisol-DHEA ratio in patients with 
schizophrenia (n=20) and bipolar disorder (n=20), on stable medication for a 
minimum of 6 weeks, and healthy age- and sex-matched control subjects (n=20). 
Steroid levels were measured from plasma samples collected at 30 minute 
intervals from 1:00 p.m. to 4:00 p.m. Cortisol levels were found to be 
significantly elevated in both patient groups compared with controls. DHEA levels 
were elevated in schizophrenic patients compared with bipolar patients and 
controls, but there was no evidence of a difference in the cortisol-DHEA ratio of 
the groups. These data suggest that afternoon hypercortisolaemia is evident in 
symptomatic bipolar and schizophrenic patients compared to controls. However, 
an elevation in DHEA levels may represent a specific endocrine marker in 
schizophrenia.  
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1. INTRODUCTION 
Abnormalities of the hypothalamic-pituitary-adrenal (HPA) axis are hypothesised 
to play a central role in the pathogenesis and aetiology of severe psychiatric 
illnesses (Raison & Miller, 2003). These abnormalities are evident at several 
levels; including decreased glucocorticoid receptor (GR) mRNA post-mortem 
(Perlman et al., 2004; Webster et al., 2002); increased ACTH and cortisol 
responses to the dexamethasone/corticotropin-releasing hormone (dex/CRH) 
challenge test (Lammers et al., 1995; Watson et al., 2004) and cortisol non-
suppression following dexamethasone challenge (DST; Dewan et al., 1982; 
Greden et al., 1982; Nelson & Davis, 1997). In many patients with schizophrenia 
and bipolar disorder these abnormalities lead to increased basal cortisol levels 
(Linkowski et al., 1985; Ryan et al., 2004). 
 Recently there has been increased interest in the role of other adrenal 
steroids such as dehydroepiandrosterone (DHEA) which, in its sulfated form 
(DHEA-S) is the most abundant in humans (Morfin, 2002). DHEA is a substrate 
for androstenedione and testosterone synthesis and may have a role as an 
adrenal androgen (Gurnell & Chatterjee, 2001). The precise mechanism of action 
of DHEA in the brain is less well known (for a comprehensive overview, see; 
Morfin, 2002) although it has been shown to have actions on membrane-bound 
receptors and is a gamma-aminobutyric acid type A (GABAA) antagonist (Hansen 
et al., 1999) as well as a sigma-1 receptor agonist (Maurice et al., 2006).  
 Importantly, DHEA (or its active metabolites, see; Muller et al., 2006) may 
possess anti-glucocorticoid properties (Kalimi et al., 1994). For example, in 
animals it has been demonstrated that DHEA protects hippocampal neurons 
against neurotoxin-induced cell death, possibly by decreasing nuclear GR levels 
(Cardounel et al., 1999). DHEA(S) has also been shown to inhibit glucocorticoid-
induced enzyme activity (Browne et al., 1992). In healthy humans, acute 
administration of DHEA has been shown to rapidly reduce circulating cortisol 
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levels (Wolf et al., 1997). Consequently, since DHEA levels appear to have 
regulatory effects on glucocorticoid action in the brain, it has been argued that 
the ratio of cortisol to DHEA most accurately reflects the degree of ‘functional’ 
hypercortisolaemia (see; Wolkowitz et al., 2001).  
 While some studies have assessed cortisol or DHEA levels in patients with 
schizophrenia and severe mood disorders, relatively few have measured both 
these steroids in the same samples. There have been several reports of elevated 
molar cortisol-DHEA ratios in patients with major depressive disorder, in both 
medicated (Michael et al., 2000) and unmedicated (Young et al., 2002) patients. 
Recently it has been shown that cortisol-DHEA ratios are also elevated in 
schizophrenia (Ritsner et al., 2004). However, many of these studies have 
reported neuroendocrine measures from a single time point. The diurnal and 
ultradian variation in hormone levels creates difficulty in interpreting such data.  
To our knowledge no previous study has examined cortisol, DHEA and the 
cortisol-DHEA ratio over multiple time-points in symptomatic patients with 
schizophrenia and bipolar disorder. 
 In this study, we sought to compare plasma cortisol and DHEA levels and 
the cortisol-DHEA ratios of symptomatic patients with schizophrenia or bipolar 
disorder and matched controls. We hypothesised that the patient groups would 
exhibit hypercortisolaemia and a significantly elevated cortisol-DHEA ratio 
compared to healthy, age- and sex-matched control subjects. 
 
2. METHODS 
2.1 Subjects 
Patients aged 18 to 65 years with a diagnosis of schizophrenia or bipolar disorder, 
confirmed using the Structured Clinical Interview for DSM-IV (SCID; First et al., 
1995), were recruited from secondary and tertiary care services in North East of 
England. The study formed part of a research program examining the efficacy of 
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glucocorticoid antagonists in schizophrenia and bipolar disorder, the results of 
which are reported elsewhere (Gallagher et al., 2005; Young et al., 2004). A 
specific attempt was made to recruit those who were in a stable clinical condition, 
but who remained symptomatic. Illness characteristics, clinical ratings and 
medication history were determined by trained psychiatrists using full history, 
case-note and medication review and standardized rating scales.  
 All patients were medication at the time of testing which had remained 
stable for a minimum of 6 weeks. Of the schizophrenic patients; 2 were taking 
carbamazepine (as a mood stabilizer), 7 were taking an antidepressant, all 20 
were taking at least one antipsychotic and 7 were taking anticholinergics. Of the 
bipolar patients; 17 were taking at least one mood stabilizer, with 13 taking at 
least one antidepressant and 11 taking an antipsychotic (see Appendix 1 for 
details). 
Healthy control subjects were recruited by advertisement and from 
hospital/university staff. All were physically healthy and had no personal or family 
history of psychiatric illness.  
After a complete description of the study, written informed consent was 
obtained from all participants; the study received full approval from the local 
ethics committee. 
 
2.2 Procedure 
In order to profile plasma cortisol and DHEA secretion, subjects were canulated in 
the antecubital fossa at 12:30 p.m. and blood samples (~5ml) collected at 30 
minute intervals from 1:00 p.m. to 4:00 p.m. (Halbreich et al., 1982). Subjects 
fasted throughout this period, remained semi-supine and did not sleep. Following 
extraction of serum by centrifugation, samples were immediately frozen and 
stored at -20°C.  
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2.3 Biochemical assays 
All assays were performed the in Psychiatry Research Laboratories, Newcastle 
University, using validated protocols. Cortisol levels were determined using Corti-
cote radioimmunoassay kits (ICN Pharmaceuticals, Costa Mesa, California). DHEA 
was measured in extracted plasma using a modified DHEA tritium 
radioimmunoassay kit (ICN) (for detailed procedure see; Gallagher et al., 2006).   
 
2.4 Statistical analysis 
Data were not normally distributed and were therefore log (base 10) transformed 
to meet the statistical assumptions permitting parametric analysis. 
Untransformed data summaries are reported for clarity. Cortisol levels, DHEA 
levels and molar cortisol-DHEA ratios were examined in separate repeated 
measures ANOVAs with log10 transformed sample (the 7 time points from 1:00 
p.m. to 4:00 p.m.) as a within subjects factor and diagnosis (bipolar, 
schizophrenic or control) as a between subjects factor. Where sphericity was 
violated, within subject degrees of freedom were adjusted using the Huynh-Feldt 
correction. The adjusted significance values are reported, though the original 
degrees of freedom are reported for clarity. Post hoc analyses were performed 
using Fisher's LSD (protected t-test).  
 
3. RESULTS 
3.1 Demographics 
Twenty schizophrenic patients, 20 bipolar patients  and 20 healthy controls were 
recruited (18 males, 2 females in all groups). There was no significant difference 
in the mean age in the groups (schizophrenic patients: 42.1 years, SD=10.3; 
bipolar patients: 48.6 years, SD=10.8; controls: 45.3 years, SD=12.4; F=1.705, 
df=2,57, p=0.191). Schizophrenic and bipolar patients did not differ in severity of 
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symptoms on the Brief Psychiatric Rating Scale (BPRS; schizophrenic patients: 
29.7, SD=9.8; bipolar patients: 30.1, SD=7.1; t=0.666, df=38, p=0.869). 
At the time of testing, all schizophrenic patients were symptomatic at the 
time of testing (see BPRS above). In addition, the mean Montgomery-Åsberg 
Depression Rating Scale (MADRS) score of the group was 12 (SD=9) and the 
mean 17-item Hamilton Depression Rating Scale (HDRS17) score was 11 (SD=8). 
The Calgary Depression Scale (CDS; Collins et al 1996) was also administered. Its 
use is preferential in schizophrenia because of its independence from negative 
symptoms and extra pyramidal side effects. The mean CDS score in the group 
was 3 (SD=4). 
All bipolar patients had persistent depressive symptoms, with 17 fulfilling 
full DSM-IV (SCID) criteria for a depressive episode. The mean Montgomery-
Åsberg Depression Rating Scale (MADRS) score of the group was 23 (SD=10) and 
the mean 17-item Hamilton Depression Rating Scale (HDRS17) score was 18 
(SD=10). The mean MADRS and HDRS17 scores of the three patients who did not 
meet SCID criteria for a current depressive episode were 8 (SD=5) and 4 
(SD=1), respectively. 
 
3.2 Neuroendocrine data 
The DHEA level at a single time point (3:30 p.m.) was missing for one bipolar 
patient. This was replaced using the calculated midpoint between the 3:00 p.m. 
and 4:00 p.m. samples for this subject. The initial sample (both cortisol and 
DHEA) was missing for one schizophrenic patient; values were replaced using the 
mean levels of the group. 
 
3.2.1 Cortisol 
See figure 1. 
A main effect of diagnosis was observed for cortisol (F=4.975, df=2,57, 
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p=0.010). Post hoc (LSD) analysis revealed that schizophrenic patients (mean 
log10 difference=0.126, 95%CI=0.044 to 0.207; p=0.003) and bipolar patients 
(mean log10 difference=0.087, 95%CI=0.005 to 0.169; p=0.037) exhibited 
significantly higher afternoon cortisol levels compared to controls. There was no 
difference between the two patient groups (mean log10 difference=0.039, 
95%CI=-0.043 to 0.120; p=0.350).  
A significant main effect of sample was also observed (F=17.878, 
df=6,342, p<0.001), indicating the diurnal change in cortisol levels although 
there was no diagnosis by sample interaction (F=0.537, df=12,342, p=0.797).  
 
3.2.2 DHEA 
See figure 1. 
A main effect of diagnosis was observed for DHEA (F=6.783, df=2,57, p=0.002). 
Post hoc (LSD) analysis revealed that schizophrenic patients had significantly 
higher afternoon DHEA levels compared to both controls (mean log10 
difference=0.187, 95%CI=0.080 to 0.294; p=0.001) and bipolar patients (mean 
log10 difference=0.146, 95%CI=0.040 to 0.253; p=0.008). There was no 
significant difference in DHEA levels between bipolar patients and controls (mean 
log10 difference=0.041, 95%CI=-0.066 to 0.147; p=0.451). 
A small but significant main effect of sample was also observed (F=2.452, 
df=6,342, p=0.046), indicating a more subtle diurnal change in DHEA levels than 
that seen in cortisol levels, although again there was no diagnosis by sample 
interaction (F=0.266, df=12,342, p=0.978).  
 
3.2.3 Cortisol-DHEA ratios 
See figure 2. 
There was no significant main effect of diagnosis in the molar cortisol-DHEA ratio 
(F=1.729, df=2,57, p=0.187). A significant main effect of sample was observed 
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(F=20.475, df=6,342, p<0.001), although there was no diagnosis by sample 
interaction (F=0.828, df=12,342, p=0.563).  
 
3.2.4 Exploratory analyses: effects of age 
The primary analyses were repeated with the inclusion of age as a covariate. In 
the analysis of cortisol levels, age was not a significant covariate (F=0.216, 
df=1,56, p=0.644). In the analysis of DHEA, age was found to be a significant 
covariate (F=19.890, df=1,56, p<0.001) although the effect of diagnostic group 
remained highly significant (F=6.068, df=2,56, p=0.004). Similarly, age was a 
significant covariate in the analysis of cortisol-DHEA ratios (F=12.421, df=1,56, 
p=0.001), although the main effect of group remained non-significant (F=0.658, 
df=2,56, p=0.522). 
 
3.2.5 Exploratory analyses: effects of medication 
The primary analyses were repeated to examine the effects of lithium. As no 
patients with schizophrenia were taking lithium, the comparison was made 
between bipolar patients on lithium (n=11), bipolar patients not on lithium (n=9), 
schizophrenic patients (n=20) and controls (n=20).  
For cortisol levels, the between group comparison revealed a significant 
main effect (F=3.920, df=3,56, p=0.013) with the bipolar patients not on lithium 
(mean log10 difference=0.128, 95%CI=0.025 to 0.232; p=0.016) and 
schizophrenic patients (mean log10 difference=0.126, 95%CI=0.044 to 0.207; 
p=0.003) having higher cortisol levels than control. No other significant 
differences were found.  
For DHEA levels, there was a significant between group main effect 
(F=4.567, df=3,56, p=0.006). Schizophrenic patients had higher DHEA levels 
than all other groups (p<0.05) although there were no other differences. 
Finally, for cortisol-DHEA ratios, there was no overall ANOVA main effect 
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observed (F=1.851, df=3,56, p=0.148). However, it is of note that the bipolar 
patients not on lithium had the highest cortisol-DHEA ratios (untransformed 
marginal mean collapsed across time: bipolar patients not on lithium, 
mean=11.01, SEM=1.27; controls, mean=9.05, SEM=0.85; bipolar patients on 
lithium, mean=8.16, SEM=1.15; schizophrenic patients, mean=7.40, SEM=0.85). 
In an exploratory  pairwise comparison, the cortisol-DHEA ratios of bipolar 
patients not on lithium were significantly higher than the schizophrenic patients 
(mean log10 difference=0.172, 95%CI=0.026 to 0.319; p=0.022).  
 
4. DISCUSSION 
The present study sought to examine afternoon plasma cortisol and DHEA levels 
and the cortisol-DHEA ratio in matched groups of schizophrenic and bipolar 
patients and healthy controls. In line with our original hypothesis, cortisol levels 
were significantly elevated in both patient groups compared with controls. 
However there was no evidence of a difference in the cortisol-DHEA ratio of the 
groups, despite an elevation in DHEA levels in schizophrenic patients compared 
with bipolar patients and controls.  
 To our knowledge there are no previous reports of cortisol-DHEA ratios in 
bipolar disorder. One post-mortem study that assessed neurosteroid levels in 
posterior cingulate and parietal cortex tissue from the Stanley Foundation 
Neuropathology Consortium collection found that pregnenolone and DHEA levels 
were higher in subjects with schizophrenia and bipolar disorder compared to 
control subjects (Marx et al., 2006).  
A potential confounding factor in this study could be the differing 
medication regimes of the two patient groups. The majority of bipolar patients 
were taking a mood stabilizer at the time of testing while all of the schizophrenic 
patients were taking antipsychotics (see Appendix 1). Some differences were 
observed in relation to the effects lithium treatment on cortisol levels and the 
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cortisol-DHEA ratio. However, it should be noted that this was part of an 
exploratory analysis only (see section 3.2.5) and the implication of this finding is 
unclear as previous animal work has shown that chronic lithium administration 
can lower frontal cortex and hippocampus DHEA(S) levels, and increase serum 
DHEA peripherally (Maayan et al., 2004). It should also be noted that the atypical 
antipsychotic clozapine has been found to decreased rat brain cortical DHEA(S) 
levels (Nechmad et al., 2003). Our results require replication in a drug-free 
sample.  
A further potential weakness is the sampling timeframe utilised in the 
present study. We carried out sampling at 30 minute intervals to account for the 
pulsatile nature of the HPA axis. However, the afternoon period (1:00 p.m. to 
4:00 p.m.) may be a relatively insensitive time to detect abnormalities between 
patients and controls and future studies should consider sampling around the 
morning peak or evening trough.  
Several recent studies have examined DHEA(S) levels in schizophrenia. 
Findings are consistent with those of the present study. Di Michele and colleagues 
found that plasma levels of DHEA were significantly elevated in 23 medicated 
patients with schizophrenia compared to matched controls (di Michele et al., 
2005). Importantly there was little evidence of an effect of medication as there 
was no significant relationship between DHEA levels and olanzapine equivalents, 
although there was a strong negative relationship between clozapine dosages and 
DHEA plasma levels in the group of patients treated with clozapine only (however 
there were only 3 patients in this comparison). In a series of studies, Ritsner and 
colleagues have also shown that plasma cortisol-DHEA and cortisol-DHEAS ratios 
were significantly higher in schizophrenia patients than in healthy comparison 
subjects. Again, no significant association was found between these ratios and 
severity of psychopathology and type or dose of antipsychotic agent (Ritsner et 
al., 2004). Interestingly, elevated cortisol levels and an elevated cortisol-DHEA(S) 
ratio have been shown to be predictive of a positive short-term response to 
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antipsychotic treatment (Ritsner et al., 2005). Similarly, elevated DHEA(S) levels 
have been found in first-episode patients, along with a trend for higher DHEAS 
levels to be associated with shorter hospitalizations (Strous et al., 2004).  
It is important to note the temporal evolution of structural changes within 
the HPA axis in psychotic illness. In a series of studies, Pariante and colleagues 
demonstrated that pituitary volumes are enlarged (by 10% compared to controls) 
in patients with first-episode psychosis while volumes are decreased (by 17% 
compared to controls) in those with ‘established’ schizophrenia (Pariante et al., 
2004). Separated by diagnosis, the numerically largest increases have been 
found in schizophrenia/ schizophreniform disorder (24%), compared to 19% 
larger in depressed patients, 16% larger in bipolar patients and 12% larger in 
those with other psychoses (Pariante et al., 2005). The patients in our study were 
recruited from secondary and tertiary care services and therefore had longer-
term, chronic illnesses. An elevation of both cortisol (Ryan et al., 2003; Ryan et 
al., 2004) and DHEA (Strous et al., 2004) levels has been found in first-episode 
schizophrenia therefore, as we observed a similar neuroendocrine profile in our 
study, this may suggest these abnormalities are stable or even represent trait 
markers of illness. However, this – and the relationship between the structural 
changes and neuroendocrine profile – remains to be confirmed in longitudinal 
studies.   
The mechanism of action for dissociable changes in cortisol and DHEA 
levels is unclear. Both steroids are mainly synthesized and secreted by the 
adrenal cortex. However, within the adult adrenal the zona fasciculata produces 
cortisol and the zona reticularis both DHEA and DHEAS (Rainey et al., 2002). It is 
therefore possible that there are differential alterations in the function or 
structure of these distinct morphological zones.  
 Recent studies have explored the use of antiglucocorticoid agents 
(Gallagher & Young, 2006), including DHEA, in the treatment of severe 
psychiatric illness. Strous and colleagues found that DHEA augmentation in 
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medicated schizophrenic patients resulted in a significant improvement in 
negative-, depressive- and anxiety symptoms which, in the case of the negative 
symptoms, correlated with the increase in plasma DHEA(S) levels (Strous et al., 
2003). Improvements in extrapyramidal symptomatology, specifically 
parkinsonism, have also been demonstrated following adjunctive DHEA treatment 
(Nachshoni et al., 2005), although it should be noted that recently Ritsner and 
colleagues found that augmenting standard treatment with DHEA (200 mg/day 
for 6 weeks) did not improve symptoms, side effects, or quality-of-life 
impairment in schizophrenia, but did improve neurocognitive functioning and 
PANSS scores (from baseline) (Ritsner et al., 2006). Interestingly, the patients 
examined in the present study went on to take part in a trial of the GR-antagonist 
mifepristone (RU-486) where positive effects were observed in neurocognitive 
function and mood in the patients with bipolar disorder (Young et al., 2004) but 
not in the patients with schizophrenia (Gallagher et al., 2005) – i.e. the group 
with elevated levels of the ‘endogenous antiglucocorticoid’ DHEA. To date there 
have been no trials of DHEA in bipolar disorder although there are case reports 
that have suggested that DHEA may induce mania in some individuals with 
(Dean, 2000; Vacheron-Trystram et al., 2002) or without (Markowitz et al., 1999) 
previous history of bipolar disorder. It should also be noted that aside from the 
putative anti-glucocorticoid actions of DHEA(S), other properties of this steroid 
have potentially important therapeutic implications. DHEA replacement in patients 
with Addison's disease (primary adrenal insufficiency) who were on standard 
glucocorticoid and mineralocorticoid replacement has been shown to improve self-
esteem and mood, and a decrease in fatigue (Hunt et al., 2000). Improvements 
in insulin sensitivity in hypoadrenal women have also been described (Dhatariya 
et al., 2005). While the efficacy of DHEA has been examined in other diverse 
clinical conditions (Cameron & Braunstein, 2005), these effects have not been 
demonstrated consistently and may warrant further examination in larger 
randomised clinical trials.  
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 In summary, our data demonstrates that afternoon hypercortisolaemia is 
evident in symptomatic bipolar and schizophrenic patients compared to controls. 
However, the elevation in DHEA levels may represent a dissociable endocrine 
marker in schizophrenia, although there was no overall change in cortisol-DHEA 
ratio in any group. Assessing the influence of individual drug treatments and 
profiling in medication-free groups should be a priority for future studies to 
increase our understanding of the pathophysiology of these illnesses and 
elucidate new avenues for treatment.   
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Figure 1: Afternoon cortisol and DHEA levels a in bipolar patients (n=20), 
schizophrenic patients (n=20) and controls (n=20). 
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a Untransformed values are presented 
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Figure 2: Molar cortisol-DHEA ratios in bipolar patients (n=20), schizophrenic 
patients (n=20) and controls (n=20). 
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Appendix 1. Medication details of bipolar and schizophrenic patients 
 
 Bipolar patients (n) Schizophrenic patients (n) 
Mood stabilizers a   
carbamazepine 3 2 
gabapentin 3 - 
lamotrigine 6 - 
lithium 11 - 
valproate 5 - 
   
Antipsychotics b   
amisulpride - 1 
clozapine - 3 
fluphenazine - 1 
haloperidol - 2 
olanzapine 3 7 
quetiapine 4 1 
risperidone 3 4 
sulpiride 1 2 
zuclopenthixol - 1 
   
Antidepressants c   
amitriptyline 1 - 
citalopram 1 - 
fluoxetine - 4 
lofepramine - 1 
mirtazapine 5 - 
paroxetine 2 - 
reboxetine - 1 
sertraline 1 - 
trazodone 1 - 
venlafaxine 6 1 
 
a included are 9 bipolar patients on combination therapies:  
lithium + lamotrigine: n=5 
valproate + lamotrigine: n=1 
lithium + carbamazepine + gabapentin: n=1 
carbamazepine + gabapentin: n=1 
lithium + valproate + carbamazepine: n=1 
 
b included are 2 schizophrenic patients on combination therapies: 
olanzapine + haloperidol: n=1 
risperidone + fluphenazine: n=1 
 
c included are 4 bipolar patients on combination therapies:  
venlafaxine + mirtazapine: n=3 
citalopram + mirtazapine: n=1 
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